Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT06238024
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 108 participants
- Sponsor
- Registry
-
NCT06238024
-
- Other papers using this trial's data
- Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06238024. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-02 (actual); primary completion 2024-06-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
- Acronym
- IRIS
- Condition
- Interleukin-6
- Condition
- Ischemic Stroke
- Condition
- Endovascular Treatment
- Intervention (Drug)
- Tocilizumab
- Intervention (Drug)
- NaCl 0.9% 100ml
- Lead sponsor
- Suzhou Municipal Hospital of Anhui Province
- Collaborator
- Xuanwu Hospital, Beijing
Record details
- Record id
cardio:ct-nct06238024- Content hash
fb10f0868e6124cd6d0e33fb4d46b06ccbee0308b18d14db984ed5bedcadf96c